A platform for collecting health data on ME/CFS and Long Covid
Unhide® Project Also Known as The Unhide® Solve Together Unified Platform
This study is trying to collect health information from adults with ME/CFS and Long Covid to help researchers better understand these conditions and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 2 Years and up |
| Sex | All |
| Sponsor | Brain Inflammation Collaborative Academic / other |
| Locations | 1 site (Delafield, Wisconsin) |
| Trial ID | NCT04806620 on ClinicalTrials.gov |
What this trial studies
Solve Together is an observational platform designed to gather clinical data on post-infectious diseases, particularly Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long Covid. Participants aged 18 and older can create profiles, complete surveys about their medical history and symptoms, and use a mobile app to track their health. The collected data will be anonymized and made available to researchers to enhance understanding of these conditions and support future clinical studies. This initiative aims to foster collaboration among patients, healthcare providers, and researchers.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older with ME/CFS, Long Covid, or those without these conditions who wish to contribute to research.
Not a fit: Patients who are under 18 or do not have ME/CFS or Long Covid may not receive direct benefits from this study.
Why it matters
Potential benefit: If successful, this platform could significantly enhance the understanding and treatment options for patients suffering from ME/CFS and Long Covid.
How similar studies have performed: While similar data collection approaches have been utilized, this specific platform is a novel initiative aimed at addressing the unique challenges of ME/CFS and Long Covid.
Eligibility criteria
Show full inclusion / exclusion criteria
Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions: * Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME/CFS), and post-acute neuropsychiatric syndrome (PANS/PANDAS). * Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder. * Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions. Inflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis. * Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions. * "Healthy" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members. * Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys. * Currently live in the United States * Be able to participate in English (stay tuned for updates about the Spanish language version) * Be willing to share symptom and health data through the platform
Where this trial is running
Delafield, Wisconsin
- Brain Inflammation Collaborative — Delafield, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Megan L Fitzgerald, PhD — Brain Inflammation Collaborative
- Study coordinator: Megan L Fitzgerald, PhD
- Email: help@braininflammationcollaborative.org
- Phone: 1-833-286-4433
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.